SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae

Tamara Cruz; Núria Mendoza; Lídia Perea; Núria Albacar; Azucena Gonzalez; Fernanda Hernandez-Gonzalez; Manel Juan; Alvar Agustí; Jacobo Sellares; Oriol Sibila; Rosa Faner

doi:10.1183/23120541.00706-2021

SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae

ERJ Open Res. 2022 Mar 7;8(1):00706-2021. doi: 10.1183/23120541.00706-2021. eCollection 2022 Jan.

Authors

Tamara Cruz^{1

2}, Núria Mendoza¹, Lídia Perea^{1

2}, Núria Albacar^{1

2

3}, Azucena Gonzalez⁴, Fernanda Hernandez-Gonzalez^{1

2

3}, Manel Juan⁴, Alvar Agustí^{1

2

3}, Jacobo Sellares^{1

2

3}, Oriol Sibila^{1

2

3

5}, Rosa Faner^{1

2

3

5}

Affiliations

¹ Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
² Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Barcelona, Spain.
³ Respiratory Insitute, Hospital Clínic, University of Barcelona, Barcelona, Spain.
⁴ Immunology Dept, Hospital Clínic, University of Barcelona. C/Villaroel 170, Barcelona, Spain.
⁵ These authors contributed equally.

Abstract

A specific T-cell response persists in the majority of COVID-19 patients 6 months after hospital discharge. This response is more prominent in those who required critical care during the acute COVID-19 episode but is reduced in patients with lung sequelae. https://bit.ly/3fBuVA4.